, where R is selected from a group comprising hydrogen and C1-C10 alkyl, R1, R2, R3 and R4 are independently selected from a group comprising hydrogen, halogen, hydroxy, C1-C10 alkyl, substituted with 1-3 halogen atoms or C6-C14 acryl, C6-C14 aryl, -OR7, -SR7 and -SO2R7, where R7 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14 aryl, C3-C10 cycloalkyl, C6-C14 aryl and C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are optionally substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino and C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, and R5 and R6 are independently selected from a group comprising hydrogen and C1-C3 alkyl, or pharmaceutically acceptable salts thereof. The invention also relates to novel cyanoquinoline derivatives of formula II
机译:氰基异喹啉化合物(版本),基于其的药物成分,低氧诱导因子(HIF)羟化酶抑制方法以及治疗和/或预防HIF伴随状况和/或红血球生成和/或氧化的方法
公开/公告号RU2457204C2
专利类型
公开/公告日2012-07-27
原文格式PDF
申请/专利权人 FAJBRODZHEN INK.;
申请/专利号RU20080134664
发明设计人 VU MIN (US);KHO VEHN-BIN (US);FLIPPIN LI EH. (US);TERTL EHRIK D. (US);DEHN SHAOTSZJAN (US);AREND MAJKL P. (US);
申请日2007-01-26
分类号C07D217/26;C07D405/12;C07D413/14;C07D417/12;A61K31/472;A61K31/4725;A61P7/06;
国家 RU
入库时间 2022-08-21 17:05:58